Article Per Year (5 Year)
p-Index From 2020 - 2025
0.562
P-Index
This Author published in this journals
All Journal Ophthalmologica Indonesiana
Sasongko, M. Bayu
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
BROLUCIZUMAB FOR WET-AGED RELATED MACULAR DEGENERATION PATIENTS : TOO GOOD TO BE TRUE Purbonegoro, Tania; Prayogo, M. Eko; Agni, A. Nurini; W., Tri Wahyu; Supanji, Supanji; S.W., Firman; Sasongko, M. Bayu
Majalah Oftalmologi Indonesia Vol 49 No S1 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/99z4g547

Abstract

Introduction & Objective: Brolucizumab is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. It showed superior anatomic outcomes compared to other anti-VEGF and noniferiority best corrected visual acuity (BCVA) results for Wet-Aged Related Macular Degeneration (Wet-AMD) patients. In Yogyakarta, its been only used in few patients and we want to report the Effectiveness and safety of brolucizumab in Wet-AMD patients in Yogyakarta. Method: In this retrospective study, all neovascular AMD (nAMD) Patients who underwent brolucizumab intravitreal injections between December 2021 and January 2023 at YAP Eye Hospital were studied. Patient’s demographic data, before and after intravitreal brolucizumab injections (central subfield thickness, intraocular pressure and BCVA) were assessed. Result :This study included 6 eyes of 6 patients ( 3 women) with a mean age of 69.5 years old. The mean follow- up period was 27 ± 10.1 weeks after the first injection of brolucizumab. Three patients were naïve nAMD patient, never got any intravitreal injections and three anti-VEGF experienced nAMD patients with ranibizumab or aflibercept injections prior to brolucizumab. Mean BCVA at baseline (before brolucizumab injection) was 0.12 decimal (6/48) and was 0.29 decimal (6/20) at the last follow-up. Five out of six patients visual acuity were improved,one patient had constant bcva. Four out of six patient central subfield thickness were reduced, none of the patient intraocular pressure increased over 21 mmhg. None of the patient reported any signs of inflammation, vasculitis, or any other ocular or systemic adverse effects. Conclusion :This limited data demonstrated that brolucizumab was safe and effective in stabilizing BCVA for both of nAMD patients who had undergone previous treatment with other anti-VEGFs agents and naive. Future larger multicenter collaborative studies are warranted.
SUTURELESS SCLERAL FIXATION OF INTRAOCULAR LENS IN APHAKIA: CHARACTERISTICS AND VISUAL OUTCOMES Rahma, Fatkhati Saida; S.W., Firman; W., Tri Wahyu; Supanji, Supanji; Sasongko, M. Bayu
Majalah Oftalmologi Indonesia Vol 49 No S1 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/nvb60j82

Abstract

Introduction & Objective: Sutureless Scleral fixation surgery is one of the secondary intraocular lens (IOL) implantation procedures for aphakic patients with absent or deficient capsular bag support that has gained more attention these days. This study aimed to describe the characteristics, indications for and visual outcomes of the patient who had undergone scleral fixation of intraocular lens at Sardjito Hospital. Methods: A retrospective cross-sectional study of 43 eyes that undergone sutureless scleral fixation intraocular lens at Sardjito Hospital, Yogyakarta. The data were collected from electronic medical records of the patient from October 2020 to December 2022. The data was analysed descriptively by presenting number and percentage for categorical variables and mean ± standard deviation (SD) for numerical variables. Outcome include pre- and postoperative uncorrected visual acuity (UCVA). Results: There were 43 eyes obtained from 40 patients who underwent scleral-fixation intraocular lens in this study, consisting of 35 males (79,55%) and 9 females (20,45%). The mean age of the subjects was 50.04 ± 19.2 years. Lens subluxation was the most of indication for surgery (32,56%), followed by intraocular lens luxation (20,93%), dropped nucleus (16,28%), lens luxation (16,28%), intraocular lens decentration (9,30%), and endophthalmitis (4,65%). Before surgery, most of the patients had visual acuity of less than 3/60 (81,4%) and after surgery, 32,56% had ?6/18, 34,88% had <6/18-6/60 and 18,60% had <6/60-3/60. Conclusion: The characteristics of patient who underwent scleral fixation intraocular lens in Sardjito Hospital was predominantly male and diagnosed with lens subluxation. There were enhancement in visual outcomes.
Sutureless Scleral Fixation of Intraocular Lens in Aphakia: Characteristics and Visual Outcomes: Oral Presentation - Observational Study - Resident Rahma, Fatkhati Saida; W., Firman S.; A, Angela Nurini; W, Tri Wahyu; Supanji; Sasongko, M. Bayu
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/gqh2r204

Abstract

Introduction & ObjectivesSutureless scleral fixation (SSF) surgery is one of the secondary intraocular lens (IOL) implantationprocedures for aphakic patients with absent or deficient capsular bag support that is beingincreasingly performed these days. This study aimed to describe the characteristics, indications for,and visual outcomes of patients who had undergone sutureless scleral fixation of intraocular lensesat Sardjito Hospital. MethodsA retrospective cross-sectional study of 43 eyes that SSF intraocular lens at Sardjito Hospital,Yogyakarta. The data were collected from electronic medical records of patients from October 2020to December 2022. The data were analyzed descriptively by presenting numbers and percentages forcategorical variables and mean ± standard deviation (SD) for numerical variables. Outcomesincluded pre- and postoperative uncorrected visual acuity (UCVA). ResultsThere were 43 eyes obtained from 40 patients who underwent SSF intraocular lens in this study,consisting of 35 males (79.55%) and 9 females (20.45%). The mean age of the subjects was 50.04 ±19.2 years. Lens subluxation was the most common indication for surgery (32.5%), followed bydropped nucleus (20.45%), intraocular lens luxation (18.18%), lens luxation (15.91%), intraocularlens decentration (9.09%), and endophthalmitis (4.55%). Before surgery, most of the patients hadvisual acuity of less than 3/60 (81.4%) and after surgery, 32.56% had ?6/18, 34.88% had <6/18-6/60,and 18.60% had <6/60-3/60. ConclusionMales predominantly underwent SSF intraocular lens surgery at Sardjito Hospital. Lens subluxationwas the most common indication for the surgery. There was an improvement in visual outcome.
Co-Authors A, Angela Nurini A. Nurini Agni Prayogo, M. Eko Purbonegoro, Tania Rahma, Fatkhati Saida S.W., Firman Supanji Supanji, Supanji W, Tri Wahyu W., Firman S. W., Tri Wahyu